RESUMO
Objectives: To show whether the prognosis of oncocytic variant of papillary carcinoma [PCOV] differs from the oncocytic variant of follicular carcinoma [FCOV], and to evaluate the importance of histological features influencing tumor recurrence and prognosis
Design: Retrospective study
Setting: Department of Pathology, Faculty of Medicine, Ege University, Izmir, Turkey
Subjects: Thirty cases diagnosed as oncocytic carcinomas of thyroid during the period of January 2000 to December 2011 were included in the study
Intervention: Demographical data, follow-up time, development of recurrence and/or distant metastasis, and macroscopical features of the tumors were evaluated. Hematoxylin-eosin stained slides of the cases were reviewed retrospectively
Main outcome measures: To show the prognostic difference of PCOV from FCOV and to evaluate the importance of histological features influencing tumor recurrence and prognosis
Results: Twenty cases were PCOV and 10 were FCOV.Two of the FCOV and one PCOV case recurred locally. None of the cases of PCOV developed distant metastasis and all of these cases are alive. Only one FCOV case with extrathyroidal extension developed distant metastasis and two cases with extrathyroidal extension recurred locally. Four FCOV cases developed metastasis and three of these died from the disease. Vascular invasion was observed in most of the FCOV, but only in one of the PCOV cases. Significant association was found between the histological type of the tumor and survival, and also the vascular invasion
Conclusion: The diagnosis of oncocytic carcinomas, whether variants of papillary or follicular carcinomas, is essential, as the presence of vascular invasion and disease-free survival differs between the two variants
RESUMO
BACKGROUND: Parafibromin is a recently defined tumor suppressor gene. The aim of our study was to determine the relationships of parafibromin expression in urothelial carcinomas (UCs) with prognostic parameters and to evaluate the use of parafibromin as a potential marker of UC. METHODS: Parafibromin expression was assessed in 49 UC specimens using immunohistochemistry. The correlations between parafibromin expression and clinical and pathologic parameters were investigated. RESULTS: Of the patients, 42 (85.7%) were male, and the mean age was 69.6 +/- 8.2 years (range, 54 to 88 years). Morphologically, the UCs were divided into two groups: papillary (n = 27) and non-papillary (n = 22). There were seven low-grade (14.3%) and 42 high-grade (85.7%) tumors. Parafibromin was negative in 13 tumors (26.5%), partially positive in 19 tumors (38.8%), and positive in 17 tumors (34.7%). Parafibromin expression was more negative in UCs from upper urinary locations (n=17) and with muscularis propria invasion (n=28), which was statistically significant (p = .009 and p = .007, respectively). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, survival, or disease-free survival. CONCLUSIONS: We found that UC cases with parafibromin positivity had less of a tendency to show muscularis propria invasion and were more commonly located in the lower urinary system. These results need to be confirmed with studies based on larger case series.